The phrase "accelerated approvals" is correct and usable in written English.
It can be used in contexts related to processes that expedite the approval of applications, products, or services, often in regulatory or business environments.
Example: "The new policy aims to streamline the process, resulting in accelerated approvals for all pending applications."
Alternatives: "fast-tracked approvals" or "expedited approvals".
That follows accelerated approvals this year for at least two other airports and a subway in Nanjing.
Bowing to appeals from the patient lobby, the FDA launched a program to allow accelerated approvals of experimental drugs for certain diseases for which no treatments existed.
Information on survival is essential for clinical trial design [ 90], accelerated approvals for new drugs [ 91], indirect drug comparisons, and economic considerations (e.g. formulary inclusion and other reimbursement decisions), particularly in the absence of head-to-head comparative clinical trials.
Drugs were categorized as benefitting from accelerated approval using FDA documents including "accelerated and restricted approvals under subpart H (drugs) and subpart E (biologics)," 28 "CDER drug and biologic accelerated approvals as of September 30 , 2011" 29 and the FDA's annual new drugs summaries.
Currently, only drugs approved through accelerated approval have this information integrated into their official labels.
Recently, this TIV vaccine was approved under the United States' accelerated approval regulation [ 4, 15].
But midodrine's maker got the drug approved in 1996 under a process known as accelerated approval, in which drugs for severe or life-threatening conditions are approved even though the evidence for their effectiveness is scant.
Avastin was given so-called accelerated approval in early 2008, a way for the F.D.A. to approve drugs for life-threatening diseases based on less than complete evidence of effectiveness.
Avastin was approved under a "fast-track" at FDA called accelerated approval.
Kyprolis, the new drug for multiple myeloma, received accelerated approval, under which drugs for life-threatening diseases can be approved with less than the usually required evidence, subject to further study.
But in 2008, the F.D.A. granted accelerated approval.
